Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

11 references·2 citing·48 second hop

FromToDepth

this work references cited by second hop

References

1980Measurement of patient outcome in arthritis4,391 cited
2002Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System1,333 cited
2003Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses944 cited
1997Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life595 cited
2001NICE: faster access to modern treatments? Analysis of guidance on health technologies299 cited
2000Assessing Quality in Decision Analytic Cost-Effectiveness Models212 cited
2003Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK175 cited
1999Economic consequences of the progression of rheumatoid arthritis in Sweden169 cited
2003Variation in the Estimation of Quality-adjusted Life-years by Different Preference-based Instruments146 cited
2002Modeling the progression of rheumatoid arthritis: A two‐country model to estimate costs and consequences of rheumatoid arthritis130 cited
2002Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis128 cited

Cited by

2006Not all “quality-adjusted life years” are equal103 cited
2006Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis84 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work